

MolMed presents at ASCO 2010 follow-up data of a Phase II trial of its TK therapy for leukaemia, showing its direct anti-leukaemic effects and its contribution to thymic activity renewal

Milan (Italy), 5 June 2010 - MolMed S.p.A. today presented at the Annual Meeting of the American Association of Clinical Oncology (ASCO) an update on long-term follow up data of a Phase II trial (TK007) of its cell-based therapy TK for high-risk leukaemia, showing that TK cells exert a direct role in fighting disease relapse, and make an important contribution to the renewal of the activity of the thymus gland (ASCO abstract 6534).

TK007 is a completed non-randomised Phase II trial (TK007) involving 50 patients, whose results were published in May 2009 by *The Lancet Oncology* (2009 10(5):489-500), demonstrating that the introduction of TK in the context of bone marrow transplants from partially compatible donors (haplo-transplants) allows to achieve a rapid and efficient immune-reconstitution, with a remarkable reduction of late transplant-related mortality and prolongation of long-term survival.

Claudio Bordignon, MolMed's chairman and CEO, comments: "These data further confirm that TK allows to provide the patients with a fully functional immune system that effectively protects them both from infections and from disease relapse, and also supports regeneration of their own immune functions, as shown by thymus reactivation. In particular, the anti-leukaemic effect is precisely due to the fact that TK cells come from a partially compatible donor, and thus are endowed with a specific allo-reactivity towards the recipient's leukaemic cells".

TK is currently investigated in a randomised Phase III trial (TK008) for high-risk leukaemia, addressing the issue of enabling safe and effective bone marrow transplants from partially compatible donors in adult recipients, without immune-suppression or immune-depletion, thereby opening the door of bone marrow transplant to all patients lacking a fully compatible donor. TK has been granted Orphan Drug designation in both the EU and the US.

* * *

Data presented by MolMed within ASCO 2010 also include four abstracts on its vascular targeting agent NGR-hTNF for the treatment of solid tumours, reporting data of three ongoing clinical trials - Phase I trial NGR013 testing safety and activity of NGR-hTNF at high doses (ASCO abstract e13091), Phase II trial NGR007 in combination with doxorubicin for the treatment of small-cell lung cancer (ASCO abstract e18043), and Phase II trial NGR005 in combination with Xelox for the treatment of colorectal cancer (ASCO abstract e14077) - and the predictive potential of angiogenic plasma biomarkers in a completed Phase I trial (ASCO abstract e13612).

About TK

TK is a cell therapy product, based on the use of genetically engineered donor T cells in association with bone marrow transplants from healthy donors, and particularly from partially compatible family donors (haplo-transplants). Add-backs of TK allow to keep the immune-protection and anti-leukaemia effects of donor T cells, while promptly controlling and abrogating the possible onset of GvHD.

About MolMed

MolMed S.p.A is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies. MolMed's pipeline includes two investigational anticancer products: TK, in Phase III for high-risk leukaemia, and NGR-hTNF, a selective vascular targeting agent for the treatment of solid tumours, in Phase III for malignant pleural mesothelioma and in Phase II in colorectal, liver, small-cell lung, non-small-cell lung and ovarian cancers. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy.

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14.5.1999 as subsequently amended.

For further information, please contact:

Holger Neecke
Director Business Development, Investor Relations
MolMed S.p.A.
phone: +39 02 21277.205
fax: +39 02 21277.325
e-mail: investor.relations@molmed.com

Elena Lungagnani
Communication Manager
MolMed S.p.A.
phone: +39 02 21277.207
fax: +39 02 21277.325
e-mail: media.relations@molmed.com

DISCLAIMER

This press release may contain certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.